Summary

U.S. Acromegaly Treatment Market Summary

The U.S. acromegaly treatment market size was estimated at USD 571.3 million in 2024 and is projected to reach USD 977.2 million by 2033, growing at a CAGR of 6.2% from 2025 to 2033. This is attributed to the rising prevalence of acromegaly and earlier diagnoses, coupled with advancements in diagnostic tools such as MRI and IGF-1 tests, improved awareness, and a better understanding of the disease’s symptoms.

Technological advances in diagnostics and the adoption of personalized treatment regimens are expected to help early detection and adherence. Strong healthcare infrastructure, insurance support, and multidisciplinary care teams are further expected to support market expansion.

Moreover, advances in treatment options, including newer somatostatin analogs, growth hormone receptor antagonists, and personalized therapies, offer improved efficacy and fewer side effects. These innovations enhance patient outcomes and expand the treatment pool, fueling market demand and encouraging further investment in research and development.

U.S. Acromegaly Treatment Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. acromegaly treatment market report based on drug class, and distribution channel:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Somatostatin Analogues (SSAs)
• Growth Hormone Receptor Antagonists (GHRAs)
• Dopamine Agonists
• Other Drug Types (Combination Therapies, Pipeline Drugs)
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources & Third-Party Perspectives
1.3.4. Primary Research
1.4. Information Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Acromegaly Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related Market Outlook
3.2. Industry Value Chain Analysis
3.3. Regulatory Framework
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.2. Market Restraint Analysis
3.4.3. Industry Challenges
3.4.4. Industry Opportunities
3.5. Industry Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.6. Market Entry Strategies
Chapter 4. Consumer Behavior Analysis
4.1. Demographic Analysis
4.2. Consumer Trends and Preferences
4.3. Factors Affecting Buying Decision
4.4. Consumer Drug Class Adoption
4.5. Observations & Recommendations
Chapter 5. U.S. Acromegaly Treatment Market: Drug Class Estimates & Trend Analysis
5.1. U.S. Acromegaly Treatment Market Drug Class: Key Takeaways
5.2. Drug Class Movement Analysis & Market Share, 2024 & 2033
5.3. U.S. Acromegaly Treatment Market Estimates & Forecast, By Drug Class, 2021 To 2033 (USD Million)
5.3.1. Somatostatin Analogues (SSAs)
5.3.1.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
5.3.2. Growth Hormone Receptor Antagonists (GHRAs)
5.3.2.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
5.3.3. Dopamine Agonists
5.3.3.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
5.3.4. Other Drug Types (Combination Therapies, Pipeline Drugs)
5.3.4.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
Chapter 6. U.S. Acromegaly Treatment Market: Distribution Channel Estimates & Trend Analysis
6.1. U.S. Acromegaly Treatment Market Distribution Channel: Key Takeaways
6.2. Distribution Channel Movement Analysis & Market Share, 2024 & 2033
6.3. U.S. Acromegaly Treatment Market Estimates & Forecast, By Distribution Channel, 2021 to 2033 (USD Million)
6.3.1. Hospital Pharmacies
6.3.1.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
6.3.2. Retail Pharmacies
6.3.2.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
6.3.3. Others
6.3.3.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
Chapter 7. U.S. Acromegaly Treatment Market - Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Heat Map/ Positioning Analysis
7.3. Strategy Mapping
7.4. Company Profiles
7.4.1. Novartis AG
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Ipsen Pharma
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Sun Pharmaceutical Industries Ltd
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Chiasma, Inc.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Crinetics Pharmaceuticals
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. WOCKHARDT
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Pfizer Inc.
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Ionis Pharmaceuticals, Inc.
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Teva Pharmaceuticals
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives